Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA.


Journal

Talanta
ISSN: 1873-3573
Titre abrégé: Talanta
Pays: Netherlands
ID NLM: 2984816R

Informations de publication

Date de publication:
01 Mar 2021
Historique:
received: 05 08 2020
revised: 06 11 2020
accepted: 09 11 2020
entrez: 31 12 2020
pubmed: 1 1 2021
medline: 15 5 2021
Statut: ppublish

Résumé

Nivolumab is a fully human immunoglobulin G4 used for the treatment of several advanced solid cancers as immune checkpoint inhibitors. There are some challenges for the quantification of mAb in plasma because IgG are present intrinsically in complex biologic matrices and this determination must be based on reliable, selective, and accurate analytical methods. This study described two validated methods carried out in two separate laboratories, one developed with a triple quadrupole tandem mass spectrometry (LC-MS/MS) and the other with high resolution mass spectrometry with an orbitrap system (LC-MS/HRMS). Both methods used full-length stable isotope-labeled nivolumab-like (Arginine

Identifiants

pubmed: 33379098
pii: S0039-9140(20)31180-2
doi: 10.1016/j.talanta.2020.121889
pii:
doi:

Substances chimiques

Nivolumab 31YO63LBSN

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

121889

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Aurélien Millet (A)

Laboratoire de Biochimie et Pharmaco-toxicologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, F-69495, Pierre Bénite, France; EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon-Sud, F-69921, Oullins, France.

Nihel Khoudour (N)

Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014, Paris, France.

Pauline Bros (P)

Promise Proteomics, 7 Parvis Louis Néel, F-38040, Grenoble, France.

Dorothée Lebert (D)

Promise Proteomics, 7 Parvis Louis Néel, F-38040, Grenoble, France.

Guillaume Picard (G)

Promise Proteomics, 7 Parvis Louis Néel, F-38040, Grenoble, France.

Christelle Machon (C)

Laboratoire de Biochimie et Pharmaco-toxicologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, F-69495, Pierre Bénite, France; EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon-Sud, F-69921, Oullins, France; Laboratoire de Chimie Analytique, Faculté de Pharmacie ISPBL, Université Lyon 1, F-69373, Lyon, France.

François Goldwasser (F)

Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM, 75014, Paris, France.

Benoit Blanchet (B)

Department of Pharmacokinetics and Pharmacochemistry, Cochin Hospital, AP-HP, CARPEM, 75014, Paris, France; UMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, University of Paris, PRES Sorbonne Paris Cité, CARPEM, 75006, Paris, France.

Jérôme Guitton (J)

Laboratoire de Biochimie et Pharmaco-toxicologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, F-69495, Pierre Bénite, France; EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine Lyon-Sud, F-69921, Oullins, France; Laboratoire de Toxicologie, Faculté de Pharmacie ISPBL, Université Lyon 1, F-69373, Lyon, France. Electronic address: jerome.guitton@univ-lyon1.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH